Thanks for sharing @hamsa - without having looked into the health economics of it in any depth, I’m working on the basis that HepB and HepC wouldn’t make attractive commercial targets, due to the low unmet medical need based on a combination of available vaccines and low incidence?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.142M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $3.2K | 1.6M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 24516803 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 10130560 | 18 |
View Market Depth
| Last trade - 13.55pm 26/06/2025 (20 minute delay) ? |
| 1AD (ASX) Chart |